Health-related quality-of-life, work productivity, and economic burden among patients with Parkinson’s disease in Japan

Yamabe, K.; Liebert, Ryan; Flores, Nicholas E.; Pashos, Chris L.

doi:10.1080/13696998.2018.1522638

Cited by 9 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five studies used the WHOQOL or its short version (WHOQOL‐BREF), 11,12,28,42,43 of which 3 studies with available data 12,28,39 were included in the meta‐analysis. Thirteen studies used the SF‐36, or its brief versions, such as SF‐12 and SF‐6D 8‐10,27,29,34,35,37,44‐47 ; 7 studies with available data were included in the meta‐analysis. Another twelve studies used EQ‐5D or EQ‐VAS 11,28,31‐33,38,40,48‐54 ; 4 studies using EQ‐5D 31,33,38,49 and 5 studies using EQ‐VAS 31‐33,38,40 with available data were included in the meta‐analysis.…”

Section: Resultsmentioning

confidence: 99%

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

et al. 2020

View full text Add to dashboard Cite

Background Studies regarding the impact of Parkinson's disease (PD) on quality of life (QOL) have reported conflicting results, and the underlying QOL domains require further study. In order to understand the association between PD and QOL, we conducted this meta‐analysis to systematically compare QOL between PD patients and healthy controls. Method The PubMed, PsycINFO, EMBASE, and Web of Science databases were systematically searched. Data were analyzed using the random‐effects model. Results Twenty studies covering 2707 PD patients and 150,661 healthy controls were included in the study. Compared with healthy controls, PD patients had significantly poorer QOL overall and in most domains with moderate to large effects sizes. Different QOL measures varied in their association with quality of life, with the Parkinson's Disease Questionnaire‐39 (PDQ‐39) having the largest effect size (standard mean difference, SMD = −1.384, 95% CI: −1.607, −1.162, Z = 12.189, P < 0.001), followed by the Europe Quality of Life Questionnaire‐visual analogue scale (EQ‐VAS) (SMD = −1.081, 95% CI: −1.578, −0.584, Z = −4.265, P < 0.001), Europe Quality of Life Questionnaire‐5D (EQ‐5D) (SMD = −0.889, 95% CI: −1.181, −0.596, Z = −5.962, P < 0.001), and the Short‐form Health Survey (SF) scales (physical dimension: SMD = −0.826, 95% CI: −1.529, −0.123, Z = −2.303, P = 0.021; mental dimension: SMD = −0.376, 95% CI: −0.732, −0.019, Z = −2.064, P = 0.039). Conclusion PD patients had lower QOL compared with healthy controls in most domains, especially in physical function and mental health. Considering the negative impact of poor QOL on daily life and functional outcomes, effective measures should be developed to improve QOL in this population.

show abstract

Section: Resultsmentioning

confidence: 99%

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Indirect costs, such as productivity loss and the provision of uncompensated care by family members, have been conservatively estimated at US$ 6.3 billion and may account for 45% of total expenses [17,18]. In Japan, direct and indirect costs were also estimated to be US$ 38,000 and US$ 25,000 per PwP [19]. This amount seems to be higher in PwP with dementia because of the greater severity of their disability.…”

Section: Introductionmentioning

confidence: 99%

Dementia-Related Functional Disability in Moderate to Advanced Parkinson’s Disease: Assessment Using the World Health Organization Disability Assessment Schedule 2.0

Chen

Hong

et al. 2019

IJERPH

View full text Add to dashboard Cite

Dementia is a common nonmotor condition among people with moderate or advanced Parkinson’s disease (PD). Undoubtedly, profound motor symptoms cause remarkable impairment in daily activities; however, dementia-related disabilities have not been thoroughly investigated, especially not with consideration of differences according to sex. The present study used the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) to compare the functional disability between men and women with PD (PwP) with and without dementia. This study employed a registry of disability evaluation and functional assessment using the Taiwan Data Bank of Persons with Disability between July 2012 and October 2018. To investigate dementia-related disability in PwP, 1:1 matching by age and Hoehn-Yahr stage was conducted, which resulted in the inclusion of 1605 study participants in each group. The present study demonstrated that among the six major domains of WHODAS 2.0, the section of “Getting alone with others” was significantly worse in both genders of PwP with dementia; however, a greater disability in fulfilling activities of daily living was only noted in male PwP with dementia but not in their female counterparts. Neither the inability to provide self-care nor participation were significantly different between the sexes. Our findings suggested that deteriorating social relationships were a dementia-related disability in all PwP at the moderate and advanced disease stages. Regarding the performance of activities of daily living, deterioration was related to dementia only in male PwP. Such disabilities could indicate cognitive impairment in people with moderate or advanced PD and could be used as an indicator for the early detection of dementia in PwP by healthcare professionals through the easier functional assessment of the WHODAS 2.0.

show abstract

“…A diversity of studies has assessed the direct medical costs of PD in developed countries [ 15 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. A prevalence-based study using a claims database from the US Medicare population reported that the PD-related direct medical costs were USD 3429 in 2018 (USD 3106.5 in 2012) [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…In Hungary, a cross-sectional questionnaire survey conducted in one neurology university clinic discovered that the direct medical costs per capita reached a value of EUR 2149.3 in 2009 (USD 5194.9 in 2012) [ 24 ]. In Japan, Yamabe et al [ 25 ] used Japan National Health and Wellness Survey data and found that the direct medical costs attributable to PD were USD 37,994 in 2014 (USD 36,645.5 in 2012). In Singapore, a study conducted by using a prevalence-based bottom-up approach estimated that the direct medical costs per person were SGD 2550 in 2009 (USD 2396.7 in 2012) [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Direct Medical Costs of Parkinson’s Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City

Zhang

Zhou

Zhang

2022

IJERPH

View full text Add to dashboard Cite

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder. This study aims to evaluate the direct medical costs of patients with PD using a large sample from an entire city and to identity the potential factors correlating with their inpatient costs in Guangzhou City, Southern China. Methods: This retrospective cross-sectional study uses data obtained from the Urban Employee-based Basic Medical Insurance (UEBMI) and the Urban Resident-based Basic Medical Insurance (URBMI) administrative claims databases in Guangzhou City from 2008 to 2012. The total sample was comprised of 2660 patients with PD. Costs were evaluated for the total sample and by types of insurance. The composition of costs was compared between the UEBMI and URBMI subgroups. The extended estimating-equations model was applied to identify the potential impact factors influencing the inpatient costs. Results: The direct medical costs per patient with PD were CNY 14,514.9 (USD 2299.4) in 2012, consisting of inpatient costs of CNY 13,551.4 and outpatient costs of CNY 963.5. The medication costs accounted for the largest part (50.3%). The inpatient costs of PD patients under the UEBMI scheme (CNY 13,651.0) were significantly higher than those of patients in the URBMI subgroup (CNY 12,402.2) (p < 0.05). The proportion of out-of-pocket spending out of inpatient and outpatient costs for UEBMI beneficiaries (24.3% and 56.1%) was much lower than that for patients under the URBMI scheme (47.9% and 76.2%). The regression analysis suggested that types of insurance, age, hospital levels, length of stay (LOS) and comorbidities were significantly correlated with the inpatient costs of patients with PD. Conclusions: The direct medical costs of patients with PD in China were high compared to the GDP per capita in Guangzhou City and different between the two evaluated types of insurance. Patients with the UEBMI scheme, of older age, with comorbidities, staying in tertiary hospitals and with longer LOS had significantly higher inpatient costs. Thus, policymakers need to reduce the gaps between the two urban insurance schemes in benefit levels, provide support for the development of a comprehensive long-term care insurance system and promote the use of telemedicine in China.

show abstract

Health-related quality-of-life, work productivity, and economic burden among patients with Parkinson’s disease in Japan

Abstract: PD was associated with poorer HRQoL, greater work productivity loss, and higher direct and indirect costs. The findings suggest that an unmet need exists among patients with PD in Japan. Improving PD treatment and management could benefit both patients and society.

Cited by 9 publications

References 29 publications

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

Dementia-Related Functional Disability in Moderate to Advanced Parkinson’s Disease: Assessment Using the World Health Organization Disability Assessment Schedule 2.0

Direct Medical Costs of Parkinson’s Disease in Southern China: A Cross-Sectional Study Based on Health Insurance Claims Data in Guangzhou City

Contact Info

Product

Resources

About